Veröffentlichungsdatum: 27 November 2020
Projektträger – zwischengeschaltetes Finanzinstitut
SCOPE FLUIDICS SA
The Promoter is a Polish med tech company developing innovative products in the field of diagnostics and health care with a focus on antibiotic resistance of bacteria and viral pathogens (including COVID-19).
The proposed transaction will support research and development (R&D) investments required to bring products to the market addressing high unmet medical needs, in a growing patient population, preserving and cultivating highly skilled employment opportunities.
- Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 10 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 20 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details will be verified during appraisal.
The Promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Unterzeichnet - 7/09/2020
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).